Co-Authors
This is a "connection" page, showing publications co-authored by Fabrizio Palmieri and Delia Goletti.
Connection Strength
3.286
-
Exploratory analysis to identify the best antigen and the best immune biomarkers to study SARS-CoV-2 infection. J Transl Med. 2021 06 26; 19(1):272.
Score: 0.238
-
Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2. Int J Infect Dis. 2021 Dec; 113 Suppl 1:S82-S87.
Score: 0.233
-
Increase in Tuberculosis Diagnostic Delay during First Wave of the COVID-19 Pandemic: Data from an Italian Infectious Disease Referral Hospital. Antibiotics (Basel). 2021 Mar 08; 10(3).
Score: 0.233
-
In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy. J Infect. 2021 04; 82(4):58-66.
Score: 0.233
-
Concurrent cavitary pulmonary tuberculosis and COVID-19 pneumonia with in vitro immune cell anergy. Infection. 2021 Oct; 49(5):1061-1064.
Score: 0.231
-
A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients. Clin Microbiol Infect. 2021 Feb; 27(2):286.e7-286.e13.
Score: 0.227
-
Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January-April 2020. Emerg Infect Dis. 2020 11; 26(11):2709-2712.
Score: 0.226
-
Characterization of QuantiFERON-TB-Plus results in latent tuberculosis infected patients with or without immune-mediated inflammatory diseases. J Infect. 2019 07; 79(1):15-23.
Score: 0.204
-
Effect of therapy on Quantiferon-Plus response in patients with active and latent tuberculosis infection. Sci Rep. 2018 10 23; 8(1):15626.
Score: 0.198
-
First description of agonist and antagonist IP-10 in urine of patients with active TB. Int J Infect Dis. 2019 Jan; 78:15-21.
Score: 0.196
-
Evaluation of IP-10 in Quantiferon-Plus as biomarker for the diagnosis of latent tuberculosis infection. Tuberculosis (Edinb). 2018 07; 111:147-153.
Score: 0.193
-
Modulation of CD4 and CD8 response to QuantiFERON-TB Plus in patients with active tuberculosis and latent tuberculosis infection followed over time during treatment. Int J Mycobacteriol. 2016 Dec; 5 Suppl 1:S141-S142.
Score: 0.173
-
Modulation of interferon-gamma response to QuantiFERON-TB-plus detected by enzyme-linked immunosorbent assay in patients with active and latent tuberculosis infection. Int J Mycobacteriol. 2016 Dec; 5 Suppl 1:S143-S144.
Score: 0.173
-
Characterization of the CD4 and CD8 T-cell response in the QuantiFERON-TB Gold Plus kit. Int J Mycobacteriol. 2016 Dec; 5 Suppl 1:S25-S26.
Score: 0.173
-
Down Syndrome patients with COVID-19 pneumonia: A high-risk category for unfavourable outcome. Int J Infect Dis. 2021 Feb; 103:607-610.
Score: 0.057
-
Postmortem Findings in Italian Patients With COVID-19: A Descriptive Full Autopsy Study of Cases With and Without Comorbidities. J Infect Dis. 2020 11 09; 222(11):1807-1815.
Score: 0.057
-
Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. Eur Respir J. 2020 07; 56(1).
Score: 0.056
-
Interplay of DDP4 and IP-10 as a Potential Mechanism for Cell Recruitment to Tuberculosis Lesions. Front Immunol. 2018; 9:1456.
Score: 0.048
-
Human CD4 T-Cells With a Naive Phenotype Produce Multiple Cytokines During Mycobacterium Tuberculosis Infection and Correlate With Active Disease. Front Immunol. 2018; 9:1119.
Score: 0.048
-
Quantitative and qualitative profiles of circulating monocytes may help identifying tuberculosis infection and disease stages. PLoS One. 2017; 12(2):e0171358.
Score: 0.044
-
The global dynamics of diabetes and tuberculosis: the impact of migration and policy implications. Int J Infect Dis. 2017 Mar; 56:45-53.
Score: 0.044